Tristram was around 18 months old when his parents noticed that he was not meeting his physical milestones. He became progressively weaker and began using a wheelchair at the age of three. It was not until he was seven years old when he was diagnosed with SMA type 2 by his neurologist. Now, as an adult, Tristram travels the world representing Australia as an elite Powerchair Football athlete and enjoys what he describes as a “very normal life”.
Pioneers in Neuroscience

8 December 2022
FIRST TREATMENT FOR THE LEADING CAUSE OF GENETIC DEATH IN CHILDREN UNDER TWO NOW FUNDED1,2
From 1 January 2023 SPINRAZA® (nusinersen) will be funded by Pharmac for the treatment of paediatric patients (18 years and younger) with infantile-onset or childhood-onset of Spinal Muscular Atrophy (SMA) with onset of symptoms prior to three years of age and infants with pre-symptomatic SMA (3 copies SMN2 or less).1,3

After 20 years in Australia and 15 in New Zealand, Biogen remains steadfast in its commitment to work fearlessly to change lives. Biogen Australia and New Zealand is proud to have highly motivated and engaged people with a strong commitment to patients. A strong culture of inclusion and diversity empowers Biogen’s people to make a positive impact on the communities they serve.

Stephen’s story: Living with Multiple Sclerosis
Stephen was 22 years old when he was diagnosed with Multiple Sclerosis (MS), a life-long autoimmune disease that damages the central nervous system (CNS). Over time, damage to the CNS can cause physical disability and impair neurological functions like motor skills, thinking and vision.

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.
June 15, 2020
TO PATIENTS, HEALTHCARE PROVIDERS, PARTNERS, AND OUR COMMUNITY
Since the early days of the pandemic, employee safety and well-being have been a top priority for Biogen. We have put in place very clear measures aimed at maintaining critical work so that we can continue delivering lifesaving medicines to people around the world.

In an unprecedented year, Biogen continued to accelerate action on key challenges of our time including equity and access, diversity and inclusion and climate and health. Read about our progress on advancing environmental, social and governance (ESG) priorities, and our goals for a healthier, more resilient and equitable future.

Our mission is clear. We are Pioneers in Neuroscience.
Office 152, 155
Fanshawe Street
Auckland, 1010
New Zealand
Phone: +64 800 852 289* (*Mon-Fri, 9am-5pm AEST)
Email: enquiriesaunz@biogen.com

We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you.